Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

142
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
142
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

175
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
175
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

122
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
122
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

201
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
201
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

95
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
95

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Withdrawal in Patients With Coronary Artery Disease.

Journal of the American College of Cardiology·2026
Same author

Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty.

JAMA network open·2026
Same author

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.

Clinical and translational science·2026
Same author

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.

Surgery·2026
Same author

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.

Surgical endoscopy·2026
Same author

Prevalence of CYP2C19 phenotypes in patients undergoing a hiatal hernia repair.

Pharmacogenetics and genomics·2026

Related Experiment Video

Updated: Apr 21, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.8K

Genes affecting warfarin response-interactive or additive?

Larisa H Cavallari1, Julio D Duarte2

  • 1Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida at Gainesville, Gainesville, FL, USA.

Journal of Clinical Pharmacology
|November 12, 2014
PubMed
Summary

Genetic variations in CYP2C9 and VKORC1 influence warfarin dosing, but explain only half of dose variability in Europeans. Further research into non-European populations is crucial for improving genotype-guided warfarin therapy.

Keywords:
CYP2C9VKORC1genotypewarfarin

More Related Videos

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.6K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Experiment Videos

Last Updated: Apr 21, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.8K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.6K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Clinical Pharmacology

Background:

  • Warfarin dosing exhibits significant inter-patient variability.
  • Cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotypes are known contributors to this variability.
  • Current genetic markers explain substantial, but not all, dose variability, particularly in European populations.

Purpose of the Study:

  • To investigate the contribution of genetic factors to warfarin dose variability.
  • To evaluate the clinical utility of genotype-guided warfarin dosing across different populations.
  • To identify gaps in current genetic understanding for warfarin pharmacogenomics.

Main Methods:

  • Analysis of CYP2C9 and VKORC1 genotypes.
  • Correlation of genotypes with warfarin dose requirements.
  • Review of clinical trial data on genotype-guided warfarin dosing.
  • Comparative analysis of genetic contributions across diverse ethnic groups.

Main Results:

  • CYP2C9 and VKORC1 genotypes significantly impact warfarin dose requirements.
  • These genetic factors, along with clinical data, explain about 50% of dose variability in Europeans.
  • The explanatory power of known genotypes is less in non-European populations.
  • Clinical trials show benefit in Europeans but not in ethnically diverse cohorts.

Conclusions:

  • Genetic variations in CYP2C9 and VKORC1 are key determinants of warfarin dose, especially in Europeans.
  • A significant portion of warfarin dose variability remains unexplained, necessitating further research.
  • Realizing the full benefit of genotype-guided warfarin dosing in diverse populations requires identifying and incorporating additional relevant genetic variants.